EAM
GPCR icon

Exome Asset Management’s Structure Therapeutics GPCR Stock Holding History

Exome Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,744
Closed -$1.11M – 85
2025
Q2 		$1.11M Sell
53,744
-49,200
-48% -$1.08M 0.83% 46
2025
Q1 		$1.78M Sell
102,944
-49,021
-32% -$1.2M 1.58% 28
2024
Q4 		$4.12M Buy
151,965
+31,800
+26% +$1.13M 3.1% 10
2024
Q3 		$5.27M Buy
+120,165
New +$4.65M 3.57% 4
2024
Q1 		– Sell
-68,100
Closed -$2.78M – 60
2023
Q4 		$2.78M Buy
+68,100
New +$3.9M 2.74% 13

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Exome Asset Management's GPCR Position: Q3 2025 in Review

Exome Asset Management sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 53,744 shares — an estimated $1.11M sold.

Exome Asset Management first reported a position in GPCR in Q4 2023 and held it in 5 quarters. The position peaked at $5.27M in Q3 2024. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

  • Exome Asset Management reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Exome Asset Management sold 53,744 Structure Therapeutics shares in Q3 2025, an estimated $1.11M.
  • Exome Asset Management first reported a position in Structure Therapeutics in Q4 2023 and held it in 5 quarters.
  • Exome Asset Management's Structure Therapeutics position peaked at $5.27M in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.